IL142372A0 - 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents - Google Patents

2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents

Info

Publication number
IL142372A0
IL142372A0 IL14237299A IL14237299A IL142372A0 IL 142372 A0 IL142372 A0 IL 142372A0 IL 14237299 A IL14237299 A IL 14237299A IL 14237299 A IL14237299 A IL 14237299A IL 142372 A0 IL142372 A0 IL 142372A0
Authority
IL
Israel
Prior art keywords
ureido
preparation
antitumor agents
thiazole derivatives
thiazole
Prior art date
Application number
IL14237299A
Other languages
English (en)
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of IL142372A0 publication Critical patent/IL142372A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL14237299A 1998-10-30 1999-10-27 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents IL142372A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9823873.6A GB9823873D0 (en) 1998-10-30 1998-10-30 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
PCT/EP1999/008307 WO2000026203A1 (fr) 1998-10-30 1999-10-27 Derives de 2-ureidothiazols, leur procede de preparation et leur utilisation comme agents antitumoraux

Publications (1)

Publication Number Publication Date
IL142372A0 true IL142372A0 (en) 2002-03-10

Family

ID=10841640

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14237299A IL142372A0 (en) 1998-10-30 1999-10-27 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents

Country Status (22)

Country Link
US (2) US6863647B2 (fr)
EP (1) EP1124811A1 (fr)
JP (1) JP2002528538A (fr)
KR (1) KR20010085984A (fr)
CN (1) CN1325390A (fr)
AR (1) AR023060A1 (fr)
AU (1) AU771166C (fr)
BR (1) BR9914868A (fr)
CA (1) CA2347060A1 (fr)
CZ (1) CZ20011413A3 (fr)
EA (1) EA200100486A1 (fr)
GB (1) GB9823873D0 (fr)
HK (1) HK1041260A1 (fr)
HU (1) HUP0104167A3 (fr)
ID (1) ID28971A (fr)
IL (1) IL142372A0 (fr)
NO (1) NO20012058L (fr)
NZ (1) NZ510967A (fr)
PL (1) PL347506A1 (fr)
SK (1) SK4752001A3 (fr)
WO (1) WO2000026203A1 (fr)
ZA (1) ZA200102869B (fr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (fr) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Aminothiazole a substituant carbone, inhibiteurs de kinases dependantes de cycline
EP1158985B1 (fr) 1999-01-13 2011-12-28 Bayer HealthCare LLC DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
ME00275B (fr) 1999-01-13 2011-02-10 Bayer Corp DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002539206A (ja) * 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1169038B9 (fr) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Inhibiteurs cycliques de proteine tyrosine kinase
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
CA2380389A1 (fr) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Derives de biaryluree
JP2003513082A (ja) 1999-11-04 2003-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド バソプレッシン拮抗物質としての非ペプチド置換されたベンゾチアゼピン類
WO2001095856A2 (fr) * 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Derive d'uree en tant qu'agent anticancereux et son procede de preparation
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
ATE357444T1 (de) 2000-08-17 2007-04-15 Lumera Corp Design und synthese von nlo-materialien für electro-optische anwendungen, die von thiophen abgeleitet sind
US6653478B2 (en) 2000-10-27 2003-11-25 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
ES2300376T3 (es) * 2000-10-27 2008-06-16 Ortho-Mcneil Pharmaceutical, Inc. Nuevas benzimidazol-2-onas sustituidas utilizadas como antagonistas del receptor de la vasopresina y como moduladores del neuropeptido y.
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
WO2002050071A1 (fr) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Inhibiteurs thiazolyl des tyrosine kinases de la famille tec
WO2002056886A1 (fr) * 2001-01-19 2002-07-25 Santen Pharmaceutical Co., Ltd. Inhibiteurs de l'angiogenese contenant un derive d'uree comme ingredient actif
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EP1256578B1 (fr) * 2001-05-11 2006-01-11 Pfizer Products Inc. Dérivés de thiazole et leur utilisation comme inhibiteurs de cdk
SE0102440D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compound
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
WO2003015778A1 (fr) * 2001-08-17 2003-02-27 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
EP1438048A1 (fr) * 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. Composes d'uree benzo fusionnes 1,4-disubstitues utilises comme inhibiteurs des cytokines
CA2465328C (fr) * 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
PL370989A1 (en) * 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
AR038703A1 (es) * 2002-02-28 2005-01-26 Novartis Ag Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
EA007099B1 (ru) 2002-03-13 2006-06-30 Янссен Фармацевтика Н. В. Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы
MXPA04008797A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Inhibidores de histona desacetilasa.
HRP20040805A2 (en) 2002-03-13 2005-04-30 Janssen Pharmaceutica N.V. Carbonylamino derivatives as novel inhibitors histone deacetylase
CA2475766C (fr) 2002-03-13 2012-06-05 Janssen Pharmaceutica N.V. Derives piperazinyl-, piperidinyl- et morpholinyl- utilises en tant que nouveaux inhibiteurs d'histone deacetylase
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
ATE381332T1 (de) 2002-05-02 2008-01-15 Merck & Co Inc Tyrosinkinase-hemmer
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2003243921B2 (en) * 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
AU2003256755A1 (en) 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
CN100497302C (zh) * 2002-09-05 2009-06-10 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途
DE10247226A1 (de) * 2002-10-10 2004-04-22 Merck Patent Gmbh Heterocyclische Amide
AR043057A1 (es) 2002-10-30 2005-07-13 Vertex Pharma Compuestos derivados de piridintiazoles como inhibidores de la quinasa rock y otras proteinas quinasa
EP1636585B2 (fr) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-urees presentant une activite d'inhibition des kinases
EP1663978B1 (fr) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
WO2005040100A1 (fr) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Derives de tetrahydro-naphthalene et d'uree
WO2005037797A1 (fr) * 2003-10-21 2005-04-28 Pharmacia Corporation Composes d'uree de pyrazole substituee utiles dans le traitement d'inflammations
BRPI0506662B8 (pt) * 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
EP2295426A1 (fr) 2004-04-30 2011-03-16 Bayer HealthCare, LLC Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2007000265A (es) * 2004-07-02 2007-07-20 Icos Corp Compuestos utiles para inhibir chk1.
KR101261305B1 (ko) 2004-07-28 2013-05-08 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로의 치환된 인돌릴알킬 아미노 유도체
CA2580767A1 (fr) 2004-09-17 2006-03-30 Whitehead Institute For Biomedical Research Composes, compositions et procedes d'inhibition de toxicite d'alpha-synucleine
CA2592118C (fr) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Derives d'uree en tant que modulateurs d'enzyme
NZ590148A (en) * 2004-12-30 2012-04-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
JP2008528448A (ja) * 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
JPWO2006073202A1 (ja) * 2005-01-04 2008-08-07 国立大学法人金沢大学 ＧＳＫ３β阻害効果に基づくがんの抑制および抗がん剤の評価方法
WO2006078621A2 (fr) * 2005-01-19 2006-07-27 Bristol-Myers Squibb Company Composes heteroaryle tenant lieu d'inhibiteurs du recepteur p2y1
TW200726764A (en) * 2005-06-27 2007-07-16 Bristol Myers Squibb Co N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
DE602006017694D1 (de) * 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (fr) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Antagonistes carbocycliques et heherocycliques du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques
ATE502924T1 (de) 2005-06-27 2011-04-15 Bristol Myers Squibb Co Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
EP1904438B1 (fr) * 2005-07-08 2012-02-29 Novo Nordisk A/S Dicycloalkylcarbamoylurées en tant qu' activateurs de glucokinase
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー／エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
EP1904467B1 (fr) * 2005-07-14 2013-05-01 Novo Nordisk A/S Activateurs de l'urée glucokinase
WO2007084391A2 (fr) * 2006-01-18 2007-07-26 Amgen Inc. Composes thiazole et procedes d'utilisation
WO2007082874A1 (fr) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Dérivés de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone désacétylase
WO2008011191A1 (fr) * 2006-07-21 2008-01-24 Replidyne, Inc. Urées hétérocycliques antibactériennes
US20110172230A1 (en) * 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP2118083A1 (fr) * 2007-01-09 2009-11-18 Novo Nordisk A/S Activateurs de la glucokinase à base d'urée
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
WO2008128986A1 (fr) * 2007-04-18 2008-10-30 Probiodrug Ag Dérivés d'urée utilisés comme inhibiteurs de la glutaminyl cyclase
WO2008131276A1 (fr) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Inhibiteurs de kinase utiles pour le traitement de maladies myéloprolifératives et autres maladies prolifératives
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
EP2173728A2 (fr) 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
JP5444365B2 (ja) * 2008-10-29 2014-03-19 デシフェラ ファーマシューティカルズ，エルエルシー 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質
US20120071475A1 (en) * 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
EP2338888A1 (fr) 2009-12-24 2011-06-29 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
MX2013005479A (es) * 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
KR101445175B1 (ko) * 2011-09-16 2014-10-06 연세대학교 산학협력단 중간엽 줄기세포의 혈관내피세포로의 분화 유도를 위한 티아졸기를 함유하는 우레아 화합물
WO2013085954A1 (fr) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Dérivés de pipéridinyl-carboxamide substitué utiles en tant qu'inhibiteurs de scd 1
WO2013085957A1 (fr) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Dérivés de pipéridinyl-pyridazinyle substitué utiles comme inhibiteurs de scd 1
CN103387551B (zh) 2012-05-11 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 噻唑类化合物及其用途
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP5934658B2 (ja) * 2013-01-29 2016-06-15 Ｊｘエネルギー株式会社 イミド−ウレア化合物及びその製造方法、グリース用増ちょう剤並びにグリース組成物
WO2015171995A1 (fr) * 2014-05-08 2015-11-12 Dana-Farber Cancer Institute, Inc. Inhibiteurs de petites molécules de pénétration du vih-1 et leurs méthodes d'utilisation
US10065934B2 (en) 2014-07-17 2018-09-04 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
WO2017027984A1 (fr) * 2015-08-20 2017-02-23 Simon Fraser University Composés et procédés de traitement anticancéreux par l'inhibition d'atg4b et le blocage de l'autophagie
CN107176951A (zh) * 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
CA3068059A1 (fr) * 2016-06-21 2017-12-28 The University Of Melbourne Activateurs de la latence du vih
EP3481810A4 (fr) * 2016-07-11 2019-05-29 Baruch S. Blumberg Institute Aminothiazoles substitués
WO2019028104A1 (fr) * 2017-08-02 2019-02-07 Alphala Co., Ltd. Nouveau composé et composition pharmaceutique le contenant
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
EP3740484B1 (fr) * 2018-01-15 2024-09-11 Aucentra Therapeutics Pty Ltd Dérivés de 5-(pyrimidin-4-yl)thiazol-2-yl urée en tant qu'agents thérapeutiques
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
CA3091951A1 (fr) * 2018-03-01 2019-09-06 Thomas Helledays Stiftelse For Medicinsk Forskning Benzodiazoles substitues et leur utilisation en therapie
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
GB201809050D0 (en) * 2018-06-01 2018-07-18 E Therapeutics Plc Modulators of tryptophan catabolism
WO2019241311A1 (fr) 2018-06-11 2019-12-19 Northeastern University Ligands sélectifs pour la modulation des canaux girk
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
PT3837256T (pt) * 2018-08-17 2023-05-23 Novartis Ag Compostos e composições de ureia como inibidores de smarca2/brm-atpase
WO2020185812A1 (fr) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Formes à l'état solide de riprétinib
TW202106684A (zh) 2019-05-03 2021-02-16 美商奇奈特生物製藥公司 Raf激酶抑制劑
WO2020252240A1 (fr) * 2019-06-14 2020-12-17 Ifm Due, Inc. Composés et compositions pour traiter des états associés à une activité de sting
AU2020308862B2 (en) * 2019-06-28 2026-03-26 Research Triangle Institute Urea derivatives as CB1 allosteric modulators
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412B1 (fr) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
JP7626910B2 (ja) 2019-10-24 2025-02-05 ピエール ファーブル メディカモン Ｒａｆキナーゼの阻害剤
EP4084779B1 (fr) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions de 1-(4-bromo-5-(1-éthyl-7-(méthylamino)-2-oxo-1,2-dihydro -1,6-naphthyridine-3-yl)-2-fluorophényl)-3-phényluree
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (fr) 2020-06-08 2021-12-16 Jing TENG Sels ou co-cristaux de {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acide acetique et leurs utilisations
WO2022060996A1 (fr) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibiteurs de raf kinases
WO2022081469A1 (fr) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibiteurs de kinases raf
EP4274824A1 (fr) 2021-01-08 2023-11-15 IFM Due, Inc. Composés hétérobicycliques ayant une urée ou un analogue et leurs compositions pour le traitement d'états associés à une activité de sting
BR112023021913A2 (pt) 2021-04-23 2024-01-16 Kinnate Biopharma Inc Tratamento de câncer com inibidor de raf
TW202325276A (zh) * 2021-10-29 2023-07-01 德商艾斯巴赫生物有限公司 結合至新穎異位結合位之病毒解旋酶抑制劑
EP4472968A1 (fr) 2022-02-03 2024-12-11 Pierre Fabre Medicament Inhibiteurs de raf kinases
JP2025066196A (ja) * 2022-03-14 2025-04-23 国立大学法人東北大学 認知機能改善剤
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
CN117186026B (zh) * 2023-08-28 2025-07-15 南通华祥医药科技有限公司 含噻唑甲氧基苯基联硫脲基团的酰胺化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH451156A (de) * 1962-09-18 1968-05-15 Ciba Geigy Verfahren zur Herstellung des neuen N-(2-Chlor-äthyl)-N'-(5-nitro-thiazolyl-2)-harnstoffes
OA01933A (fr) * 1965-04-06 1970-02-04 Pechiney Saint Gobain Dérivés du thiazole.
FR7428M (fr) * 1968-05-06 1969-11-12
BE754783A (fr) * 1969-08-15 1971-02-12 May & Baker Ltd Derives thiazolyl a usage herbicide leur preparation et les compositions qui les contiennent
HU168393B (fr) 1973-11-09 1976-04-28
ZA747255B (en) * 1973-11-30 1975-11-26 Ici Ltd Herbicidal heterocyclic compounds
JPS57136579A (en) * 1981-01-21 1982-08-23 Mitsui Toatsu Chem Inc Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
HU209839B (en) 1989-04-13 1994-11-28 T Kom Za Promishlena Mikrobiol Process for producing ureido-thiazol derivatives and pharmaceutical compositions containing them
HUP0004421A3 (en) 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
EP0928790B1 (fr) * 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Dérivés du thiazole

Also Published As

Publication number Publication date
AU1044700A (en) 2000-05-22
KR20010085984A (ko) 2001-09-07
ID28971A (id) 2001-07-19
CN1325390A (zh) 2001-12-05
AU771166B2 (en) 2004-03-18
SK4752001A3 (en) 2002-02-05
HUP0104167A3 (en) 2003-12-29
BR9914868A (pt) 2001-07-03
EP1124811A1 (fr) 2001-08-22
ZA200102869B (en) 2001-10-10
CZ20011413A3 (cs) 2001-09-12
EA200100486A1 (ru) 2001-12-24
US20040157827A1 (en) 2004-08-12
AU771166C (en) 2005-01-13
AR023060A1 (es) 2002-09-04
GB9823873D0 (en) 1998-12-30
NO20012058L (no) 2001-06-28
NO20012058D0 (no) 2001-04-26
HK1041260A1 (zh) 2002-07-05
US6863647B2 (en) 2005-03-08
WO2000026203A1 (fr) 2000-05-11
CA2347060A1 (fr) 2000-05-11
PL347506A1 (en) 2002-04-08
NZ510967A (en) 2003-10-31
HUP0104167A2 (hu) 2002-03-28
US20030187040A1 (en) 2003-10-02
JP2002528538A (ja) 2002-09-03

Similar Documents

Publication Publication Date Title
PL347506A1 (en) 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
IL147923A0 (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
IL147925A0 (en) 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
PL347505A1 (en) 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents
HUP0201225A3 (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agent and process for their preparation
HUP0202492A3 (en) Arylmethyl-carbonylamino-thiazole derivatives process for their preparation and their use as antitumor agents
HU9602305D0 (en) 4-heterocyclyl-substituted quinazoline derivatives, process for their preparation and their use as anti-cancer agents
HUP0103111A3 (en) Epothilone derivatives, process for their preparation and their use
HUP0203425A3 (en) Quinazoline derivatives, process for their preparation and their use
HUP0004747A3 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation
AU1596097A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
HUP0100927A3 (en) Antitumor substituted indene-derivatives, process for their preparation, medicaments containing them and their use
IL159570A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
GR3036824T3 (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
HUP0104033A3 (en) 1-benzoyl-tetrahydropyridazine derivatives, process for their preparation, their use and medicaments containing the compounds
HUP0104620A3 (en) 2-phenylpyran-4-one derivatives, process for their preparation and medicaments containing them
HUP0104819A3 (en) Chroman derivatives, their use intermediate and process for their preparation
HUP0204572A3 (en) Substituierte bisindolylmaleinimide derivatives, process for their preparation and use and pharmaceutcial compositions containing them
SI0863139T1 (en) Benzoxazindione derivatives, process for their preparation and their use
HUP0102518A3 (en) 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them
HUP0204393A3 (en) Pluraflavins and derivatives thereof, process for their preparation and use thereof
SI1406899T1 (sl) Derivati fenilacetamido-tiazola, postopek za njihovo pripravo in njihova uporaba kot antitumorska sredstva
GB9613987D0 (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
GB9602163D0 (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents